IRELAND – Medtronic, a global leader in medical technology, has acquired Fortimedix Surgical, a Netherlands-based medtech company specializing in articulating instrument technology for robotic and non-robotic endoscopic procedures.
Fortimedix announced the acquisition through a LinkedIn post, describing the deal as a “unique opportunity to leverage our articulating instrument technology for application across patient therapies.”
Fortimedix is known for its proprietary laser-cut technology, which transforms low-cost metal tubes into flexible articulating shafts with hundreds of moving parts.
This innovation enhances the performance and affordability of endoscopic instruments, setting a new standard for minimally invasive surgery (MIS) and endoluminal procedures.
“Because we do not employ conventional parts machining and assembly, we’re able to realize exceptional performance at cost levels otherwise not achievable,” the company notes on its website.
The company’s articulating instruments are designed to enable early-stage surgical intervention endoscopically, helping advance MIS techniques to improve patient outcomes and expand the therapeutic reach of endoscopic procedures.
Fortimedix’s legacy and global footprint
Headquartered in Geleen, The Netherlands, with a U.S. subsidiary in San Diego, California, Fortimedix has spent nearly two decades as a trusted partner in the medical device industry.
The company originally gained recognition as a global leader in contract stent manufacturing before pivoting toward innovative surgical instrument development.
Fortimedix’s mission has remained focused on driving the evolution of minimally invasive surgery across various specialties to enhance the quality of life for patients worldwide.
Medtronic’s strategic acquisition approach
The acquisition aligns with Medtronic’s “smart tuck-in M&A” strategy, as outlined by CEO Geoff Martha during the company’s fiscal second-quarter earnings call.
Martha emphasized that Medtronic is focusing on acquiring assets in high-growth markets and well-established business segments that require additional support to maintain their momentum.
“This is an important part of our growth algorithm,” Martha said. “The type of M&A we want to do is more tuck-in… prioritizing areas that align with our leadership team’s strategic focus, including high-growth markets and segments.“
Fortimedix’s advanced instrument technology complements Medtronic’s existing portfolio, particularly in the high-growth minimally invasive surgery market.
The acquisition reflects Medtronic’s commitment to innovation and expanding its solutions for robotic-assisted and endoscopic procedures.
Although specific financial details of the deal remain undisclosed, this acquisition is expected to bolster Medtronic’s presence in the minimally invasive surgical space, enhancing its ability to offer comprehensive solutions for improving patient care.
